Monitoring Mechanical Assisted Cough
Launched by CORPORACION PARC TAULI · Jul 12, 2017
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
A cross-sectional observational study was performed with patients with NMD who had PFC below 160l/min according to Mechanical insufflation- exsufflation (MI-E ) criteria to assit the cough.
Exclusion criteria were age \<18 years, patients who had undergone tracheostomy, exacerbated or with psychiatric problems and patients with relative contraindications (bullous emphysema background, risk of pneumothorax or recent barotrauma).
MI- E study protocol An original protocol was established to perform treatment assessment with Cough Assitst T70 MI-E device® Phillips Respironics. Protocol based ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with NMD who had PFC below 160l/min according to Mechanical insufflation- exsufflation (MI-E ) criteria to assit the cough.
- Exclusion Criteria:
- • age \<18 years,
- • patients who had undergone tracheostomy, exacerbated or with psychiatric problems
- • patients with relative contraindications (bullous emphysema background, risk of pneumothorax or recent barotrauma).
About Corporacion Parc Tauli
Corporación Parc Taulí is a leading healthcare organization based in Sabadell, Spain, known for its commitment to advancing medical research and clinical excellence. With a focus on innovative healthcare solutions, the organization integrates cutting-edge technology and multidisciplinary collaboration to enhance patient outcomes. As a sponsor of clinical trials, Corporación Parc Taulí emphasizes ethical practices, rigorous scientific methodologies, and robust data management to contribute to the development of new therapies and improve healthcare standards. Their dedication to research and patient care positions them as a vital player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Manel Lujan, MD
Study Director
Corporacion Parc Tauli
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials